Abstract
Guidelines recommend triple therapy as a treatment option for patients with asthma who remain symptomatic on inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) was FDA approved for COPD in 2017 and asthma in 2020. This study examined the baseline characteristics and treatment patterns of elderly patients with asthma initiating FF/UMEC/VI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
